Medifast Inc (MED)
ROA
Obliczenia
|
2023/Q4 (31 gru 2023) |
2023/Q3 (30 wrz 2023) |
2023/Q2 (30 cze 2023) |
2023/Q1 (31 mar 2023) |
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | 99 415 | 119 898 | 132 922 | 141 755 | 143 568 | 151 072 | 156 899 | 164 749 |
| Aktywa razem | w tys. USD | 309 908 | 320 019 | 318 725 | 321 606 | 316 213 | 326 351 | 340 550 | 421 435 |
| ROA | 32,08% | 37,47% | 41,70% | 44,08% | 45,40% | 46,29% | 46,07% | 39,09% |
2023/Q4 obliczenia
ROA = Zysk netto (ttm) ÷ Aktywa razem
= $99 415K ÷ $309 908K
= 32,08%
Analiza porównawcza
2023/Q4
Nazwa spółki
Symbol
ROA
Medifast Inc
MED
32,08%
Amphastar Pharmaceuticals Inc
AMPH
9,09%
Arcus Biosciences Inc
RCUS
-28,04%
Catalyst Pharmaceuticals Inc
CPRX
15,19%
Collegium Pharmaceutical Inc
COLL
4,21%
Dynavax Technologies Corp.
DVAX
-0,64%
Innoviva Inc
INVA
14,45%
Ironwood Pharmaceuticals Inc
IRWD
-212,76%
Ligand Pharmaceuticals, Inc.
LGND
6,63%
Myriad Genetics, Inc.
MYGN
-22,97%
Xencor Inc
XNCR
-13,23%